Blood concentration curve of cyclosporine: Impact of itraconazole in lung transplant recipients

Transplantation

Volumn 83, Issue 8, 2007, Pages 1130-1133

  Irani, Sarosh ^a   Fattinger, Karin ^a   Schmid Mahler, Cornelia ^a   Achermann, Eva ^a   Speich, Rudolf ^a   Boehler, Annette ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Schweizerische Nationalfonds SNF   (Switzerland)

Author keywords

Area under the curve; Cyclosporine; Itraconazole; Lung transplantation; Therapeutic drug monitoring

Indexed keywords

CLARITHROMYCIN; CYCLOSPORIN A; ITRACONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MYCOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; ITRACONAZOLE; LUNG TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 34247544923     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000259724.44008.9d     Document Type: Article

References (18)

1. Trulock EP, Edwards LB, Taylor DO, Boucek MM, Keck BM, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: Twenty-second Official Adult Lung and Heart-Lung Transplant Report-2005. J Heart Lung Transplant 2005; 24: 956.
2. Kovarik JM, Mueller EA, van Bree JB, Arns W, Renner E, Kutz K. Within-day consistency in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant patients. Ther Drug Monit 1994; 16: 232.
3. Kovarik JM, Mueller EA, van Bree JB, et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation - a multicenter investigation in kidney transplant patients. Transplantation 1994; 58: 658.
4. Reynaud-Gaubert M, Viard L, Girault D, et al. Improved absorption and bioavailability of cyclosporine A from a microemulsion formulation in lung transplant recipients affected with cystic fibrosis. Transplant Proc 1997; 29: 2450.
5. Kesten S, Scavuzzo M, Chaparro C, Szalai JP. Pharmacokinetic profile and variability of cyclosporine versus neoral in patients with cystic fibrosis after lung transplantation. Pharmacotherapy 1998; 18: 847.
6. Trull A, Steel L, Sharples L, et al. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients. Ther Drug Monit 1999; 21: 17.
7. Marsh CL. Abbreviated pharmacokinetic profiles in area-under-the-curve monitoring of cyclosporine therapy in de novo renal transplant patients treated with Sandimmune or Neoral. Neoral study group. Ther Drug Monit 1999; 21: 27.
8. Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999; 68: 1356.
9. Giese T, Zeier M, Schemmer P, et al. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: A novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation 2004; 77: 339.
10. Florea NR, Capitano B, Nightingale CH, Hull D, Leitz GJ, Nicolau DP. Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. Transplant Proc 2003; 35: 2873.
11. Wimberley SL, Haug MT III, Shermock KM, et al. Enhanced cyclosporine-itraconazole interaction with cola in lung transplant recipients. Clin Transplant 2001; 15: 116.
12. Lomaestro BM, Piatek MA. Update on drug interactions with azole antifungal agents. Ann Pharmacother 1998; 32: 915.
13. Kramer MR, Marshall SE, Denning DW, et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med 1990; 113: 327.
14. Kramer MR, Merin G, Rudis E, et al. Dose adjustment and cost of itraconazole prophylaxis in lung transplant recipients receiving cyclosporine and tacrolimus (FK 506). Transplant Proc 1997; 29: 2657.
15. Warrens AN, Waters JB, Salama AD, Lechler RI. Improving the therapeutic monitoring of cyclosporin A. Clin Transplant 1999; 13: 193.
16. Kahan BD, Dunn J, Fitts C, et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 1995; 59: 505.
17. Sud K, Singh B, Krishna VS, et al. Unpredictable cyclosporin-fluconazole interaction in renal transplant recipients. Nephrol Dial Transplant 1999; 14: 1698.
18. Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: Clinical and pharmacokinetic study. Eur J Clin Pharmacol 2005; 61: 567.